Casdatifan Clinical Trials (2026): 7 Studies for Healthy Participants & Advanced Clear Cell Renal Cell Carcinoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
7 Casdatifan clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including Healthy Participants & Advanced Clear Cell Renal Cell Carcinoma) and 2,338 total planned enrollment. 2 Phase 3 Casdatifan trials and 1 Phase 2 are listed. 3 Casdatifan clinical trials are actively recruiting at 62 U.S. sites across 28 states. Most recent activity: NCT07000149 (Jul 2032).
Where to Participate: All Casdatifan Trial Sites in the U.S. (62 sites across 28 states)
Every actively recruiting Casdatifantrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Research Site | Birmingham35294 | NCT05536141 | Map |
| AZ | Research Site | Gilbert85234 | NCT07011719 | Map |
| AZ | Research Site | Goodyear85338 | NCT07011719 | Map |
| AZ | Research Site | Phoenix85054 | NCT07011719 | Map |
| CA | Research Site | Duarte91010 | NCT07011719 | Map |
| CA | Research Site | La Jolla92103 | NCT07011719 | Map |
| CA | Research Site | Los Angeles90095 | NCT07011719 | Map |
| CA | Research Site | Sacramento95817 | NCT07011719 | Map |
| CA | Research Site | San Diego92093 | NCT05536141 | Map |
| CA | Research Site | San Diego92103 | NCT07011719 | Map |
| CA | Research Site | Santa Monica90404 | NCT05536141 | Map |
| CT | Research Site | New Haven06519 | NCT07011719 | Map |
| FL | Research Site | Jacksonville32224 | NCT07011719 | Map |
| FL | Research Site | Miami33136 | NCT05536141 | Map |
| FL | Research Site | Miami33136 | NCT07011719 | Map |
| FL | Research Site | Orlando32804 | NCT07011719 | Map |
| GA | Research Site | Atlanta30322-1013 | NCT05536141 | Map |
| GA | Research Site | Atlanta30318 | NCT07011719 | Map |
| GA | Research Site | Atlanta30322 | NCT07011719 | Map |
| GA | Research Site | Newnan30265 | NCT07011719 | Map |
| IL | Research Site | Zion60099 | NCT07011719 | Map |
| IN | Research Site | Indianapolis46202 | NCT07011719 | Map |
| KY | Research Site | Louisville40202 | NCT05536141 | Map |
| KY | Research Site | Louisville40207 | NCT07011719 | Map |
| LA | Research Site | Jefferson70121 | NCT07011719 | Map |
| LA | Research Site | New Orleans70121 | NCT05536141 | Map |
| MD | Research Site | Baltimore21287 | NCT05536141 | Map |
| MD | Research Site | Baltimore21287 | NCT07011719 | Map |
| MA | Brigham and Women's Hospital | Boston02215 | NCT07397611 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT07397611 | Map |
| MA | Research Site | Boston02215 | NCT05536141 | Map |
| MA | Research Site | Boston02114 | NCT07011719 | Map |
| MA | Research Site | Boston02215 | NCT07011719 | Map |
| MI | Research Site | Detroit48201 | NCT05536141 | Map |
| MI | Research Site | Detroit48202 | NCT05536141 | Map |
| MN | Research Site | Rochester55905 | NCT07011719 | Map |
| MO | Research Site | St Louis63110 | NCT07011719 | Map |
| NE | Research Site | Omaha68124 | NCT05536141 | Map |
| NE | Research Site | Omaha68198 | NCT07011719 | Map |
| NJ | Research Site | New Brunswick08903 | NCT07011719 | Map |
| NY | Research Site | Buffalo14263 | NCT07011719 | Map |
| NY | Research Site | New York10029 | NCT05536141 | Map |
| NY | Research Site | New York10065 | NCT05536141 | Map |
| NY | Research Site | Rochester14642 | NCT07011719 | Map |
| NC | Research Site | Chapel Hill27514 | NCT07011719 | Map |
| OH | Research Site | Cleveland44106 | NCT05536141 | Map |
| OH | Research Site | Cleveland44195 | NCT05536141 | Map |
| OH | Research Site | Cleveland44106 | NCT07011719 | Map |
| OR | Research Site | Portland97212 | NCT07011719 | Map |
| PA | Research Site | Monroeville15146 | NCT07011719 | Map |
| PA | Research Site | Pittsburgh15232 | NCT05536141 | Map |
| SC | Research Site | Charleston29425 | NCT07011719 | Map |
| TN | Research Site | Nashville37203 | NCT05536141 | Map |
| TN | Research Site | Nashville37240 | NCT05536141 | Map |
| TN | Research Site | Nashville37203 | NCT07011719 | Map |
| TN | Research Site | Nashville37232 | NCT07011719 | Map |
| TX | Research Site | Dallas75390 | NCT07011719 | Map |
| TX | Research Site | Lubbock79430 | NCT07011719 | Map |
| TX | Research Site | San Antonio78229 | NCT05536141 | Map |
| UT | Research Site | Salt Lake City84112 | NCT07011719 | Map |
| VA | Research Site | Charlottesville22903 | NCT07011719 | Map |
| WA | Research Site | Seattle98109 | NCT07011719 | Map |
Casdatifan clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | Total |
|---|---|---|---|---|
| P1 | 1 | 3 | 4 | |
| P2 | 1 | 1 | ||
| P3 | 1 | 1 | 2 |
Recruiting Casdatifan clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07011719 | Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma | P3 | Metastatic Clear Cell Renal Cell Carcinoma | 720 | Sep 2025 |
| NCT07397611 | Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC | P2 | Renal Cell Carcinoma | 32 | Mar 2026 |
| NCT05536141 | ARC-20A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors | P1 | Clear Cell Renal Cell Carcinoma | 362 | Oct 2022 |
Casdatifan clinical trials by indication
Healthy Participants (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06919991 | ARC-29 | P1 | completed | Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29) |
| NCT05999513 | ARC-28 | P1 | completed | A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers |
| NCT05117554 | ARC-14 | P1 | completed | Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers |
Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07397611 | — | P2 | recruiting | Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC |
Metastatic Clear Cell Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07011719 | — | P3 | recruiting | Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma |
Advanced Clear Cell Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07000149 | eVOLVE-RCC02 | P3 | active not recruiting | A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC |
Clear Cell Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05536141 | ARC-20 | P1 | recruiting | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors |
Casdatifan pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| eVOLVE-RCC02 | NCT07000149 | P3 | active not recruiting | Advanced Clear Cell Renal Cell Carcinoma | 1,116 | — |
All Casdatifan trials (7)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07000149 | eVOLVE-RCC02 | A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC | P3 | active not recruiting | 1,116 | AstraZeneca | Jul 2025 |
| NCT07011719 | Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma | P3 | recruiting | 720 | Arcus Biosciences, Inc. | Sep 2025 | |
| NCT07397611 | Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC | P2 | recruiting | 32 | Dana-Farber Cancer Institute | Mar 2026 | |
| NCT05536141 | ARC-20 | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors | P1 | recruiting | 362 | Arcus Biosciences, Inc. | Oct 2022 |
| NCT06919991 | ARC-29 | Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29) | P1 | completed | 14 | Arcus Biosciences, Inc. | May 2025 |
| NCT05999513 | ARC-28 | A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers | P1 | completed | 24 | Arcus Biosciences, Inc. | Aug 2023 |
| NCT05117554 | ARC-14 | Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers | P1 | completed | 70 | Arcus Biosciences, Inc. | Nov 2021 |
Casdatifan clinical trials: frequently asked questions
- How many Casdatifan clinical trials are there?
- 7 Casdatifan clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 3 are marked completed.
- Are Casdatifan clinical trials recruiting in 2026?
- Yes — 3 Casdatifan trials are actively recruiting in 2026, with 62 U.S. sites across 28 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Casdatifan being studied for?
- Casdatifan is being studied for Healthy Participants, Advanced Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasm, Metastatic Clear Cell Renal Cell Carcinoma and 4 more. The trials are grouped by indication on this page.
- What phase is Casdatifan in?
- Casdatifan clinical trials span 2 Phase 3, 1 Phase 2, 4 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Casdatifan clinical trials?
- The lead sponsor across the most Casdatifan trials is Arcus Biosciences, Inc., with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Casdatifanas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: